의약품 제조 시장 : 제형별, 의약품 개발 유형별, 투여 경로별, 약물별, 연령대별, 유통 채널별, 치료 영역별 - 세계 예측(2025-2030년)

The Pharmaceutical Manufacturing Market was valued at USD 620.68 billion in 2023, expected to reach USD 672.44 billion in 2024, and is projected to grow at a CAGR of 8.66%, to USD 1,110.17 billion by 2030.

The pharmaceutical manufacturing sector encompasses the production, development, and commercialization of drugs and medical therapies, with a focus on quality, efficiency, and safety in the production of medicinal products. The necessity of this sector is underpinned by the growing global health demands, increasing prevalence of chronic diseases, and the continuous need for innovative therapeutics. Its applications span across the production of APIs (Active Pharmaceutical Ingredients), formulation of finished dosage forms, and advancements in biotechnology. The end-use scope includes hospitals, clinics, research institutes, and retail pharmacies. Key growth factors influencing this market include technological advancements such as automation and AI integration, growing R&D investments, and supportive government policies. Additionally, the rising trend towards personalized medicine and biologics offers significant growth opportunities. Companies can capitalize on these trends by investing in biotech R&D, enhancing their production capabilities, and adopting sustainable practices to reduce environmental impact.

However, the market faces several limitations and challenges, such as stringent regulatory requirements, high costs of drug development, and the complexities involved in biotechnology integration. The global pandemic has also highlighted vulnerabilities in supply chains, reinforcing the need for more resilient systems. Market players are encouraged to explore areas of innovation like digital health tools, advanced drug delivery systems, and the use of big data analytics for optimizing manufacturing processes. Additionally, developing countries present opportunities for market expansion due to increasing healthcare expenditure. The market is highly competitive, with continuous pressure to innovate, demanding agile strategies to maintain market share. Companies should focus on collaborative partnerships, open innovation, and strategic acquisitions to drive growth and overcome existing barriers. Overall, the pharmaceutical manufacturing market is characterized by its dynamic nature, driven by both scientific innovation and regulatory landscapes, thus requiring stakeholders to maintain a proactive and strategic approach to navigate and thrive in this challenging environment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmaceutical Manufacturing Market

The Pharmaceutical Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in global demand for vaccines and drugs
  • Growing pharmaceutical R&D spending
  • Growth in geriatric population and incidence rate of chronic disorders
• Market Restraints
  • High costs and complexities associated with the pharma production
• Market Opportunities
  • Rise in the investment and funding programs in the pharmaceutical manufacturing sector
  • Emergence of novel pharmaceutical manufacturing technologies
• Market Challenges
  • Stringent government regulations for pharmaceutical companies

Porter's Five Forces: A Strategic Tool for Navigating the Pharmaceutical Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmaceutical Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmaceutical Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmaceutical Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmaceutical Manufacturing Market

A detailed market share analysis in the Pharmaceutical Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmaceutical Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmaceutical Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Pharmaceutical Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Lupin Limited, Piramal Pharma Limited, Asymchem, Inc., Recipharm AB, Biocon Limited, AbbVie Inc., Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Pfizer, Inc., Merck KGaA, Amgen Inc., Advent Pharma Ltd., Johnson & Johnson Services, Inc., Azurity Pharmaceuticals, Inc., Famar Group, Zeon Lifesciences Ltd., Actiza Pharmaceutical Pvt. Ltd., Cipla Limited, Aenova Group GmbH, Boehringer Ingelheim International GmbH, Moderna, Inc., Thermo Fisher Scientific Inc., Sun Pharmaceutical Industries Ltd., BioNTech SE, Lonza Group AG, Novartis AG, F. Hoffmann-La Roche Ltd., Emcure Pharmaceuticals Limited, Veranova, L.P., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Sanofi S.A., Novo Nordisk A/S, Glenmark Pharmaceuticals Ltd., Abbott Laboratories, GlaxoSmithKline PLC, and McKesson Corporation.

Market Segmentation & Coverage

This research report categorizes the Pharmaceutical Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Formulation, market is studied across Capsules, Injectable, Powders, Sprays, Suspensions, and Tablets.
• Based on Drug Development Type, market is studied across In-House and Outsource.
• Based on Route of Administration, market is studied across Inhalations, Oral, Parenteral, and Topical.
• Based on Drugs, market is studied across Over-the-Counter (OTC) Medicines and Prescription Medicines.
• Based on Age Group, market is studied across Adults, Children & Adolescents, and Geriatric.
• Based on Distribution Channel, market is studied across Non-Retail and Retail.
• Based on Therapy Area, market is studied across Allergy, Cardiovascular Diseases, Dermatology, Diabetes, Gastroenterology, Infectious Disease, Neurology, Oncology, Ophthalmology, Pain Management, Psychiatry, Pulmonary, Renal Disease, and Respiratory Diseases.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in global demand for vaccines and drugs
    • 5.1.1.2. Growing pharmaceutical R&D spending
    • 5.1.1.3. Growth in geriatric population and incidence rate of chronic disorders
  • 5.1.2. Restraints
    • 5.1.2.1. High costs and complexities associated with the pharma production
  • 5.1.3. Opportunities
    • 5.1.3.1. Rise in the investment and funding programs in the pharmaceutical manufacturing sector
    • 5.1.3.2. Emergence of novel pharmaceutical manufacturing technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent government regulations for pharmaceutical companies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Formulation: Surging investment to support robust research and development of injectable formulations
  • 5.2.2. Drug Development Type: Increasing use of outsourced pharmaceutical manufacturing due to its cost effectiveness
  • 5.2.3. Route of Administration: Rising research and development activities parenteral drug delivery with rising prevalence of chronic disease
  • 5.2.4. Drugs: Inclination toward Over-the-counter (OTC) drugs
  • 5.2.5. Age Group: Significant need for drug formulations to treat geriatric medical conditions
  • 5.2.6. Distribution Channel: Penetration of non-retail distribution channels for pharmaceuticals
  • 5.2.7. Therapy Area: Wave of innovations toward development of new oncology treatment modalities
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization
  • 5.5.1. List of Top Selling Prescription and Over-the-Counter Drugs in 2022

6. Pharmaceutical Manufacturing Market, by Formulation

• 6.1. Introduction
• 6.2. Capsules
• 6.3. Injectable
• 6.4. Powders
• 6.5. Sprays
• 6.6. Suspensions
• 6.7. Tablets

7. Pharmaceutical Manufacturing Market, by Drug Development Type

• 7.1. Introduction
• 7.2. In-House
• 7.3. Outsource

8. Pharmaceutical Manufacturing Market, by Route of Administration

• 8.1. Introduction
• 8.2. Inhalations
• 8.3. Oral
• 8.4. Parenteral
• 8.5. Topical

9. Pharmaceutical Manufacturing Market, by Drugs

• 9.1. Introduction
• 9.2. Over-the-Counter (OTC) Medicines
• 9.3. Prescription Medicines

10. Pharmaceutical Manufacturing Market, by Age Group

• 10.1. Introduction
• 10.2. Adults
• 10.3. Children & Adolescents
• 10.4. Geriatric

11. Pharmaceutical Manufacturing Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Non-Retail
• 11.3. Retail

12. Pharmaceutical Manufacturing Market, by Therapy Area

• 12.1. Introduction
• 12.2. Allergy
• 12.3. Cardiovascular Diseases
• 12.4. Dermatology
• 12.5. Diabetes
• 12.6. Gastroenterology
• 12.7. Infectious Disease
• 12.8. Neurology
• 12.9. Oncology
• 12.10. Ophthalmology
• 12.11. Pain Management
• 12.12. Psychiatry
• 12.13. Pulmonary
• 12.14. Renal Disease
• 12.15. Respiratory Diseases

13. Americas Pharmaceutical Manufacturing Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Pharmaceutical Manufacturing Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Pharmaceutical Manufacturing Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2023
• 16.2. FPNV Positioning Matrix, 2023
• 16.3. Competitive Scenario Analysis
  • 16.3.1. INR 15,000 Crore Proposed in Pharma Sector, India
  • 16.3.2. Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes
  • 16.3.3. Novo, Torrent may Widen Tie-Up
  • 16.3.4. U.S. FDA Approves Bristol Myers Squibb's Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
  • 16.3.5. Finnish Manufacturing Facility to Get EUR 50 Million Expansion
  • 16.3.6. Aenova and Galvita Enter Strategic Partnership
  • 16.3.7. Novo Nordisk Invests EUR 2.1 Billion in Hillerod Manufacturing Expansion
  • 16.3.8. Eli Lilly Adds USD 1.6 Billion to its Manufacturing Spending Plan in Indiana
  • 16.3.9. FDA Approves Novartis Millburn Facility for U.S. Commercial Production of Pluvicto
  • 16.3.10. Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
  • 16.3.11. Pfizer Acquires Abzena's Biologic Manufacturing Facility

Companies Mentioned

• 1. AstraZeneca PLC
• 2. Lupin Limited
• 3. Piramal Pharma Limited
• 4. Asymchem, Inc.
• 5. Recipharm AB
• 6. Biocon Limited
• 7. AbbVie Inc.
• 8. Bayer AG
• 9. Takeda Pharmaceutical Company Limited
• 10. Eli Lilly and Company
• 11. Pfizer, Inc.
• 12. Merck KGaA
• 13. Amgen Inc.
• 14. Advent Pharma Ltd.
• 15. Johnson & Johnson Services, Inc.
• 16. Azurity Pharmaceuticals, Inc.
• 17. Famar Group
• 18. Zeon Lifesciences Ltd.
• 19. Actiza Pharmaceutical Pvt. Ltd.
• 20. Cipla Limited
• 21. Aenova Group GmbH
• 22. Boehringer Ingelheim International GmbH
• 23. Moderna, Inc.
• 24. Thermo Fisher Scientific Inc.
• 25. Sun Pharmaceutical Industries Ltd.
• 26. BioNTech SE
• 27. Lonza Group AG
• 28. Novartis AG
• 29. F. Hoffmann-La Roche Ltd.
• 30. Emcure Pharmaceuticals Limited
• 31. Veranova, L.P.
• 32. Bristol-Myers Squibb Company
• 33. Gilead Sciences, Inc.
• 34. Sanofi S.A.
• 35. Novo Nordisk A/S
• 36. Glenmark Pharmaceuticals Ltd.
• 37. Abbott Laboratories
• 38. GlaxoSmithKline PLC
• 39. McKesson Corporation